Dimensional Fund Advisors LP boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,223,409 shares of the company’s stock after buying an additional 1,002 shares during the period. Dimensional Fund Advisors LP owned about 0.25% of Zoetis worth $58,062,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Sandy Spring Bank boosted its stake in shares of Zoetis by 9.2% in the second quarter. Sandy Spring Bank now owns 30,367 shares of the company’s stock worth $1,442,000 after buying an additional 2,566 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Zoetis by 21.7% in the second quarter. Teacher Retirement System of Texas now owns 41,432 shares of the company’s stock worth $1,966,000 after buying an additional 7,380 shares in the last quarter. SECOR Capital Advisors LP bought a new stake in shares of Zoetis during the second quarter worth about $2,683,000. UBS Asset Management Americas Inc. boosted its stake in shares of Zoetis by 1.2% in the second quarter. UBS Asset Management Americas Inc. now owns 1,407,531 shares of the company’s stock worth $66,802,000 after buying an additional 16,612 shares in the last quarter. Finally, Schroder Investment Management Group boosted its stake in shares of Zoetis by 239.1% in the second quarter. Schroder Investment Management Group now owns 4,680 shares of the company’s stock worth $222,000 after buying an additional 3,300 shares in the last quarter. Hedge funds and other institutional investors own 93.12% of the company’s stock.
Zoetis Inc. (NYSE:ZTS) traded down 0.53% during mid-day trading on Tuesday, hitting $52.08. The stock had a trading volume of 463,385 shares. The stock has a market capitalization of $25.78 billion, a P/E ratio of 40.56 and a beta of 1.00. Zoetis Inc. has a 52 week low of $38.26 and a 52 week high of $52.64. The company’s 50 day moving average is $51.28 and its 200-day moving average is $48.54.
Zoetis (NYSE:ZTS) last announced its earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.05. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Zoetis had a return on equity of 77.58% and a net margin of 13.15%. Zoetis’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.43 earnings per share. On average, analysts expect that Zoetis Inc. will post $1.91 EPS for the current fiscal year.
A number of equities research analysts have recently issued reports on ZTS shares. Jefferies Group reiterated a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research note on Wednesday, September 14th. Bank of America Corp. started coverage on Zoetis in a research note on Thursday, September 29th. They set a “buy” rating and a $60.00 price objective on the stock. Guggenheim reiterated a “positive” rating and set a $60.00 price objective on shares of Zoetis in a research note on Monday, August 22nd. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $53.00 price objective on the stock in a research note on Wednesday, June 15th. Finally, Citigroup Inc. upped their price objective on Zoetis from $50.00 to $53.00 and gave the stock a “neutral” rating in a research note on Thursday, August 4th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Zoetis has an average rating of “Buy” and a consensus target price of $55.27.
In related news, insider Andrew Fenton sold 13,870 shares of Zoetis stock in a transaction on Friday, September 2nd. The stock was sold at an average price of $51.25, for a total transaction of $710,837.50. Following the sale, the insider now directly owns 17,719 shares in the company, valued at $908,098.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Heidi C. Chen sold 32,097 shares of Zoetis stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $50.98, for a total value of $1,636,305.06. Following the sale, the insider now owns 46,060 shares in the company, valued at $2,348,138.80. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.